Evolent Clinical Guideline 2008 for Brain Computed Tomography (CT)

Guideline Number: Evolent_CG_2008	**Applicable Codes**	
"Evolent" refers to Evolent Health LLC and Evolent Specialty Services, Inc. 		
Original Date: September 1997	**Last Revised Date:** July 2025	**Implementation Date:** January 2026

TABLE OF CONTENTS

STATEMENT

General Information

- *It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- *Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*
- *The guideline criteria in the following sections were developed utilizing evidence-based and peer-reviewed resources from medical publications and societal organization guidelines as well as from widely accepted standard of care, best practice recommendations.*

Special Note

Brain Computed Tomography (CT) and Computed Tomography Angiography (CTA) are not approvable simultaneously unless they meet the criteria described below in the Indications for **Brain CT/Brain CTA** combination studies section. If there is a combination request for an overlapping body part, either requested at the same time or sequentially (within the past 3 months) the results of the prior study should show one or more of the following:

- Inconclusive or show a need for additional or follow up imaging evaluation
- The office notes should clearly document an indication why overlapping imaging is needed and how it will change management for the patient.

(See **Combination Studies** section for indicated combinations below)

Purpose

Computed tomography (CT) is an imaging technique used to view the structures of the brain and is useful in evaluating pathologies in the brain. It provides more detailed information on head trauma, brain tumors, stroke, and other pathologies in the brain than regular radiographs.

Important Note: Brain MRI is preferred to Brain CT in most circumstances where the patient can tolerate MRI and sufficient time is available to schedule the MRI examination. Assessment of subarachnoid hemorrhage, acute trauma, or bone abnormalities of the calvarium (fracture, etc.) may be better imaged with CT. CT is also appropriate in an urgent situation where MRI is not readily available (stroke, increased ICP, CNS infection).

INDICATIONS

Headache

Evaluation of Headache [1,2]

- Acute, sudden onset headache (< 4 weeks), with any ONE of the following (no contraindication to MRI is needed):
  - A personal or family history (brother, sister, parent, or child) of brain aneurysm or AVM (arteriovenous malformation)
  - < 48 hours of "worst headache in my life" or "thunderclap" headache (Sudden onset new headache reaching maximum intensity within 2-3 minutes, lasting more than 5 minutes)
  - Prior history of stroke or intracranial bleed
  - Known coagulopathy or on anticoagulation
- New onset headache (< 3 months with no prior history of headache) with any ONE of the following (no contraindication to MRI is needed):
  - Fever
  - Subacute head trauma
  - Acute, new, or fluctuating neurologic deficits, such as sensory deficits, limb weakness, abnormal reflexes (pathological, asymmetric, hyperreflexia), speech difficulties, visual loss, lack of coordination, or mental status changes or with signs of increased intracranial pressure (papilledema).
  - Migraine with atypical/complex aura (such as motor, brainstem or retinal auras which may be characterized by motor weakness, balance issues, vertigo, slurred speech, visional loss and/or double vision)
    - **NOTE**: Imaging is not indicated for typical migraine symptoms characterized by visual and/or sensory and/or speech/language symptoms AND the absence of motor, brainstem or retinal symptoms. Typical migraines develop gradually, last one hour or less and are completely reversible
  - Severe unilateral headache with radiation to or from the neck, associated with suspicion of carotid or vertebral artery dissection
- New onset headache with any ONE of the following when MRI is **contraindicated** or cannot be performed:
  - History of cancer or significantly immunocompromised
  - Age $\geq$ 50
  - Related to activity or event (sexual activity, exertion, Valsalva, position), new or progressively worsening [3]
  - Persistent or progressively worsening during a course of physician-directed treatment [1]

- Chronic headache (>3 months) and any ONE of the following when MRI is **contraindicated** or cannot be performed:
  - Change in character or pattern (e.g. increased severity, frequency or duration)
- Cluster headaches or other trigeminal-autonomic cephalalgias (paroxysmal hemicrania, hemicrania continua, short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA)) once to eliminate secondary causes

Additional Indications in the Pediatric Population (<18) When None of the Above Apply *(4,5)*

- Persistent headache and any ONE of the following (no contraindication to MRI is needed)
  - Immune deficiency
  - History of neoplasm
  - History of congenital heart disease
  - Coagulopathy
  - See **Imaging in Known Genetic Conditions** for additional indications
- Persistent headache and any ONE of the following when MRI is **contraindicated** or cannot be performed:
  - Age < 6 years old
  - Occipital location
  - Documentation of absence of family history of headache
  - Concern for increased intracranial pressure with symptoms such as recurring headaches after waking

Neurological Symptoms or Deficits (6–10)

- Acute, new, fluctuating, or persistent neurologic symptoms or deficits such as, sensory deficits, limb weakness, abnormal reflexes (pathological, asymmetric, hyperreflexia), speech difficulties, visual loss, lack of coordination, or mental status changes.

Stroke and Vascular Disease

Evaluation of Known or Suspected Stroke *(11,12)*

- Suspected stroke with any acute, new, or fluctuating symptoms or deficits such as sensory deficits, limb weakness, speech difficulties, visual loss, lack of coordination, or mental status changes (see **Background**)
- History of stroke and ONE of the following:
  - No prior workup when MRI is **contraindicated** or cannot be performed
  - New neurologic signs or symptoms

- Suspected stroke with:
  - A personal or first-degree family history (brother, sister, parent, or child) of aneurysm OR
  - Known coagulopathy or on anticoagulation
- Symptoms of transient ischemic attack (TIA) (episodic neurologic symptoms such as sensory deficits, limb weakness, speech difficulties, visual loss, lack of coordination, or mental status changes) when MRI is **contraindicated** or cannot be performed
- See **Imaging in Known Genetic Conditions** section for additional indications (including for HbSS sickle cell disease or HbSβ0 thalassemia)

Evaluation of Known or Suspected Vascular Disease [13]

- Evaluation of suspected acute subarachnoid hemorrhage (SAH)
- Follow-up for known hemorrhage, hematoma, or vascular abnormalities [11]
- Suspected central venous thrombosis and ANY ONE of the following when MRI is **contraindicated** or cannot be performed:
  - Patient has a hypercoagulable state such as pregnancy, post-partum, prothrombotic conditions (acquired or genetic), malignancy, oral contraceptive use, recent infection, recent trauma or covid-19
  - Documentation of concern for central venous thrombosis is specified
  - Papilledema or signs/symptoms of increased intracranial pressure
- Known Moyamoya disease or reversible cerebral vasoconstriction with any new or changing neurological signs or symptoms when MRI is **contraindicated** or cannot be performed

Head Trauma

Evaluation of Known or Suspected Trauma [14,15]

- Known or suspected trauma or injury to the head with documentation of one or more of the following acute, new, or fluctuating:
  - Focal neurologic findings
  - Motor changes
  - Mental status changes
  - Amnesia
  - Vomiting
  - Seizures
  - Headache
  - Signs of increased intracranial pressure

- Known coagulopathy or on anticoagulation
- Known or suspected skull fracture by physical exam and/or prior imaging
- Repeat scan 24 hours post head trauma for anticoagulated patients with suspected diagnosis of delayed subdural hematoma
- Post concussive syndrome if persistent or disabling symptoms and imaging has not been performed
- Subacute or chronic traumatic brain injury with new cognitive and/or neurologic deficit when MRI is **contraindicated** or cannot be performed

Suspected Malignancy [16,17]

- Bone tumor or abnormality of the skull on prior imaging (CT or x-ray) [18]
- Suspected brain tumor with any acute, new, or fluctuating neurologic symptoms or deficits such as sensory deficits, limb weakness, abnormal reflexes (pathological, asymmetric, hyperreflexia), speech difficulties, visual loss, lack of coordination, or mental status changes when MRI is **contraindicated** or cannot be performed
- Lesion on prior imaging with atypical features when MRI is **contraindicated** or cannot be performed

Note: For pituitary disorders, if MRI is contraindicated or cannot be performed (see Evolent CG 2054 for Temporal Bone, Mastoid, Orbits, Sella, Internal Auditory Canal CT for Sella CT or Evolent CG 2012 for Brain MRI for indications)

Known Malignancy

MRI is the ideal modality to follow-up meningioma, pituitary tumors, low grade tumors, neurocutaneous syndromes, and screening/restaging/surveillance for non-CNS cancers. CT should only be used when MRI is **contraindicated** or cannot be performed (see ECG 2012 for Brain MRI for indications)

Seizure Disorders

Evaluation of Known or Suspected Seizure Disorder

When MRI is contraindicated or cannot be performed [19]

- New onset of unprovoked seizure [20]
- Newly identified change in seizure activity/pattern

Infection and Inflammation

Evaluation of Known or Suspected Infection or Inflammatory Disease

When MRI is contraindicated or cannot be performed [21]

- Suspected intracranial abscess or brain infection with acute altered mental status or with positive lab findings (such as elevated WBCs) **OR** follow-up assessment during or after

treatment completed.

- Meningitis with positive signs and symptoms (such as fever, headache, mental status changes, stiff neck) **OR** with positive lab findings (such as elevated white blood cells or abnormal lumbar puncture fluid exam)
- Suspected encephalitis with headache and altered mental status or follow-up as clinically warranted
- Endocarditis with suspected septic emboli
- Vasculitis
    - Central Nervous System (CNS) involvement in patients with known or suspected vasculitis or autoimmune disease with abnormal inflammatory markers or autoimmune antibodies
    - Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up when MRI is contraindicated or cannot be performed [22]
- Immunocompromised patient (e.g., transplant recipients, HIV with CD4<200, primary immunodeficiency syndromes, hematologic malignancies) with focal neurologic symptoms, headaches, behavioral, cognitive or personality changes

Evaluation of Cognitive Impairment

When MRI is contraindicated or cannot be performed [23,24]

- Evaluation for mild cognitive impairment or dementia with all of the following:
    - Objective measures demonstrate impairment (MMSE/MoCA < 26 or other mental status instruments (see **Background**) or mild cognitive impairment on neuropsychological testing)
    - Full lab evaluation (thyroid function tests, CBC, CMP, and B12) has been completed and if abnormal, has been treated and the cognitive difficulty persists

Movement Disorders [7,25]

- For evaluation of acute onset of a movement disorder with concern for stroke or hemorrhage
- For evaluation of suspected Parkinson's with atypical features or unresponsive to levodopa when MRI is **contraindicated** or cannot be performed

Note: Atypical parkinsonian syndromes include progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and dementia with Lewy bodies.

- For the evaluation of other movement disorders to exclude a structural lesion (i.e., suspected Huntington disease, chorea, hemiballismus, atypical dystonia)

Note: Imaging is not indicated in essential tremor, Tourette' syndrome or isolated focal dystonia (e.g., blepharospasm, cervical dystonia, laryngeal dystonia, oromandibular

dystonia, writer's dystonia) [25,26]

Cranial Nerve and Vision Abnormalities

Vision Abnormalities

When MRI is contraindicated or cannot be performed

- Abnormal eye findings on physical or neurologic examination that suggest CNS pathology (such as papilledema, pathologic nystagmus, optic atrophy, ocular nerve palsies, new onset anisocoria, visual field deficits) [8]
- Binocular diplopia with concern for CNS pathology after comprehensive eye evaluation [8]
- Horner's syndrome with signs/symptoms localizing the lesion to the brain (vertigo, altered facial sensation, contralateral CN IV palsy, crossed motor/sensory signs) [27,28]

Other Cranial Nerve Disorders [1,29]

When MRI is contraindicated or cannot be performed

- Trigeminal (CN V) neuralgia or neuropathy
- Occipital Neuralgia with atypical features (such as burning versus stabbing pain, referred pain to the face/ear, tinnitus, visual disturbances) to exclude a structural lesion [30]
- Hemifacial spasm (CN VII)
- Facial Nerve Paresis / Bell's Palsy (CN VII) with atypical features (such as bilateral involvement, multiple episodes, slow resolution beyond three weeks, incomplete/no improvement at three months, or facial twitching/spasms prior to onset) [29,31–33]
- Clinical evidence of cranial nerve (CN IX, X, XI, and/or XII) deficits or dysfunction (such as dysphagia, shoulder/neck movement abnormalities, tongue movement abnormalities, vocal fold movement or sensation abnormalities)
- Bulbar symptoms (such as difficulty in chewing, dysarthria, dysphagia, and dysphonia) and/or bulbar signs (such as atrophy and fasciculations of the tongue, weakness of the facial muscles, palatal weakness, absent gag reflex) [29]
- Pseudobulbar symptoms (such as dysphagia, dysarthria, sudden stereotyped emotional outbursts that are not reflective of mood) and/or pseudobulbar signs (such as spastic tongue, facial weakness, exaggerated gag/jaw jerk) [34]

Congenital Abnormalities

- Evaluation of Known or Suspected Congenital Abnormalities
  - Known or suspected congenital abnormality with any acute, new, or fluctuating neurologic, motor, or mental status changes
  - Craniosynostosis and other skull deformities [35]
  - Prior treatment **OR** treatment planned for congenital abnormality

- Evaluation of Known or Suspected Congenital Abnormalities **when MRI is contraindicated or cannot be performed**
  - Evaluation of macrocephaly in an infant/child <18 with previously abnormal US, abnormal neurodevelopmental examination, signs of increased ICP or closed anterior fontanelle [36]
  - Evaluation of microcephaly and age < 18 years old [37]
  - Cerebral palsy and ONE of the following [38]:
    - Etiology has not been established in the neonatal period
    - There is change in the expected clinical or developmental profile and concern for progressive neurological disorder
  - See **Imaging in Known Genetic Conditions** section for additional indications

  Note: For evaluation of known or suspected hydrocephalus see section on CSF abnormalities, below.

Cerebrospinal Fluid Abnormalities

- Evaluation of Known or Suspected CSF Abnormalities
  - Evaluation of suspected hydrocephalus with any acute, new, or fluctuating neurologic, motor, or mental status changes
  - Follow up of known hydrocephalus with new symptoms or to plan/monitor treatment
  - Known or suspected normal pressure hydrocephalus (NPH) [39]
    - With symptoms of gait difficulty, cognitive disturbance, and/or urinary incontinence
  - Follow-up shunt evaluation and ONE of the following [40]
    - Baseline imaging following placement or revision
    - 6-12 months after placement or revision
    - Clinical concern for shunt malfunction
  - Evaluation of known or suspected cerebrospinal fluid (CSF) leakage [41]
  - Cisternography for intermittent and complex CSF rhinorrhea/otorrhea (CSF fluid should always be confirmed with laboratory testing (Beta-2 transferrin assay) first) [41,42]
- Evaluation of Known or Suspected CSF Abnormalities **when MRI is contraindicated or cannot be performed**
  - For initial evaluation of a suspected Arnold Chiari malformation [43,44]
  - Follow-up imaging of a known type II or type III Arnold Chiari malformation. For Arnold Chiari type I, follow-up imaging only if new or changing signs/symptoms [43–45]
  - Known syrinx or syringomyelia
  - Suspected spontaneous intra-cranial hypotension with distinct postural headache

(other symptoms include nausea, vomiting, dizziness, tinnitus, diplopia, neck pain or imbalance) [1,46]

Other Indications

- Prior to lumbar puncture in patients with suspected increased intracranial pressure or at risk for herniation

Other Indications when MRI is contraindicated or cannot be performed

- Vertigo associated with any ONE of the following [6]
  - Signs or symptoms suggestive of a possible CNS lesion (such as a positive HINTS test, ataxia, dysarthria, visual loss, double vision, weakness, mental status change, hearing loss, tinnitus or a change in sensation)
  - Progressive unilateral/asymmetric hearing loss and/or tinnitus
  - Concern for stroke with known risk factors for cerebrovascular disease (such as hypertension, smoking, obesity, hypercholesterolemia)
  - Concern for central vertigo (source within the CNS) based on findings on neurologic examination and/or vestibular testing (such as skew deviation, vertical nystagmus, head thrust test, and/or videonystagmography (VNG) / electronystagmography (ENG) testing results suggesting a likely CNS etiology)

NOTE: "Vertigo" is the sensation that a person and/or their surroundings are moving. There are many vague, nonspecific terms that are often used instead including "dizzy", "light-headed", "woozy", "groggy", or "giddy". The reviewer should examine the record to determine if the patient is experiencing vertigo or another condition (such as presyncope, ataxia, anxiety, arrhythmia). If it is not clear what condition is being described, clarification should be requested.

- Diagnosis of central sleep apnea on polysomnogram
  - Children > 1 year [47]
  - Adults in the absence of heart failure, chronic opioid use, high altitude, or treatment emergent central sleep apnea **AND** concern for a central neurological cause (Chiari malformation, tumor, infectious/inflammatory disease) **OR** with an abnormal neurological exam
- Syncope with documented clinical concern for seizure or associated neurological signs or symptoms [48]
- Cyclical vomiting syndrome or abdominal migraine with any localizing neurological symptoms [49,50]
- Psychological changes with neurological deficits on exam or after completion of a full neurological assessment that suggests a possible neurologic cause [51]
- Child < 18 years with global developmental delay **OR** a developmental delay with abnormal neurological examination or abnormal EEG [52]

- Unexplained event (BRUE) formerly apparent life-threatening event (ALTE) in infants < 1 year with concern for neurological cause based on history and exam [53]

Note: Imaging is not indicated in low-risk patients

PREOPERATIVE OR POSTOPERATIVE ASSESSMENT

When not otherwise specified in the guideline:

Preoperative Evaluation:

- Imaging of the area requested is needed to develop a surgical plan

Postoperative Evaluation:

- Known or suspected complications
- A clinical reason is provided how imaging may change management

NOTE: This section applies only within the first few months following surgery

FURTHER EVALUATION OF INDETERMINATE FINDINGS ON PRIOR IMAGING

Unless follow up is otherwise specified within the guideline:

- For initial evaluation of an inconclusive finding on a prior imaging report that requires further clarification
- One follow-up exam of a prior indeterminate MR/CT finding to ensure no suspicious interval change has occurred. (No further surveillance unless specified as highly suspicious or change was found on last follow-up exam)

IMAGING IN KNOWN GENETIC CONDITIONS

- Achondroplasia [54]:
  - Once (to evaluate the corticomedullary junction; typically done in infancy)
- Sickle Cell Disease [55,56]:
  - When needed to screen for silent stroke
  - Abnormal Transcranial Doppler Velocity > 200 cm/s

Combination Studies for Imaging in Known Genetic Conditions

NOTE: When medical necessity is met for an individual study **AND** conscious sedation is

required (such as for young pediatric patients or patients with significant developmental delay), the entire combination is indicated

Brain CT and Brain CTA

- Sickle Cell Disease [55,56]:
  - When needed to screen for silent stroke
  - Abnormal Transcranial Doppler Velocity > 200 cm/s
  - New neurologic or cognitive concerns (including TIA, no formal testing required)
  - When cessation or changing frequency of transfusions is under consideration

OTHER COMBINATION STUDIES WITH BRAIN CT

Note: When medical necessity is met for an individual study **AND** conscious sedation is required (such as for young pediatric patients or patients with significant developmental delay), the entire combination is indicated

Note: These body regions might be evaluated separately or in combination as documented in the clinical notes by physical examination findings (e.g., localization to a particular segment of the neuroaxis), patient history, and other available information, including prior imaging.

Brain CT and Brain CTA

- Recent ischemic stroke
- Recent transient ischemic attack (TIA) when MRI is contraindicated or cannot be performed [11,57]
- Acute, sudden onset of headache with personal history of a vascular abnormality or first-degree family history of aneurysm [1,13]
- Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH [1]
- Headache associated with exercise, exertion, or sexual activity when MRI is contraindicated or cannot be performed [2]
- Suspected central venous thrombosis and MRI is contraindicated or cannot be performed and ANY ONE of the following [11]:
  - Patient has a hypercoagulable state such as pregnancy, post-partum, prothrombotic conditions (acquired or genetic), malignancy, oral contraceptive use, recent infection, recent trauma or Covid-19
  - Documentation of concern for central venous thrombosis is specified
  - Papilledema or signs/symptoms of increased intracranial pressure
- Known Moyamoya disease [12,58] or reversible cerebral vasoconstriction with any new or changing neurological signs or symptoms [1,59]

- **NOTE**: For this indication, when Brain CT is ordered in combination with Brain CTA, a contraindication to MRI is not needed

- Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies when MRI is contraindicated or cannot be performed [13]
- Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up when MRI is contraindicated or cannot be performed [13,22,60]

Brain CT and Brain/Neck CTA [11,12]

- Recent ischemic stroke
- Recent transient ischemic attack (TIA) when MRI is contraindicated or cannot be performed [11,57]
- History of stroke and ONE of the following:
  - No prior workup when MRI is contraindicated or cannot be performed
  - New neurologic signs or symptoms
- Suspected or known carotid or vertebral artery dissection with focal or lateralizing neurological deficits

Note: MRA and CTA are generally comparable noninvasive imaging alternatives, each with their own advantages and disadvantages. Brain MRI can alternatively be combined with Brain CTA/Neck CTA.

Brain/Cervical Spine/Thoracic Spine/Lumbar Spine CT

When MRI is contraindicated or CANNOT be performed or surgeon preference

- For initial evaluation of a suspected Arnold Chiari malformation
- Follow-up imaging of a known type II or type III Arnold Chiari malformation. For Arnold Chiari type I, follow-up imaging only if new or changing signs/symptoms [43]
- Oncological Applications (e.g., primary nervous system, metastatic) [16]
  - Drop metastasis from brain or spine (CT spine imaging in this scenario is usually CT myelogram)
  - Suspected leptomeningeal carcinomatosis
  - Tumor evaluation and monitoring in neurocutaneous syndromes
- CSF leak highly suspected and supported by patient history and/or physical exam findings (e.g., known or suspected spontaneous intracranial hypotension (SIH), post lumbar puncture headache, post spinal surgery headache, orthostatic headache, rhinorrhea or otorrhea, or cerebrospinal-venous fistula (CT myelogram)) [61]

Brain/Orbit CT [8,62]

- If MRI is contraindicated or cannot be performed:
  - Optic neuropathy or unilateral optic disk swelling of unclear etiology to distinguish between a compressive lesion of the optic nerve, optic neuritis, ischemic optic neuropathy (arteritic or non-arteritic), central retinal vein occlusion, or optic nerve infiltrative disorders
  - Bilateral optic disk swelling (papilledema) with vision loss

Combination Studies for Malignancy for Initial Staging or Restaging

Unless otherwise specified in this guideline, indication for combination studies for malignancy for initial staging or restaging:

- Concurrent studies to include CT or MRI of any of the following areas as appropriate depending on the cancer: Abdomen, Brain, Chest, Neck, Pelvis, Cervical Spine, Thoracic Spine or Lumbar Spine

CODING AND STANDARDS

Codes

70450, 70460, 70470, +0722T

Applicable Lines of Business

☒	CHIP (Children's Health Insurance Program)
☒	Commercial
☒	Exchange/Marketplace
☒	Medicaid
☒	Medicare Advantage

BACKGROUND

Contraindications and Preferred Studies

- Contraindications and reasons why a CT/CTA cannot be performed may include: impaired renal function, significant allergy to IV contrast, pregnancy (depending on

trimester).

- Contraindications and reasons why an MRI/MRA cannot be performed may include: impaired renal function, claustrophobia, non-MRI compatible devices (such as non-compatible defibrillator or pacemaker), metallic fragments in a high-risk location, patient exceeds weight limit/dimensions of MRI machine.

Computed Tomography (CT) versus Magnetic Resonance Imaging (MRI)

Generally, magnetic resonance imaging is the preferred imaging technique for evaluating the brain parenchyma, and CT is preferable for evaluating subarachnoid hemorrhage. CT is faster and more readily available than MRI and is often used in urgent clinical situations.

Stroke/TIA

Imaging for Stroke – Individuals presenting with symptoms of acute stroke should receive prompt imaging to determine whether they are candidates for treatment with tissue plasminogen activator. Non-contrast CT can evaluate for hemorrhage that would exclude the individual from reperfusion therapy.

Memory Status Instruments

Cut off values for cognitive impairment

Mini-Cog < 3

Memory Impairment Screen < 5

Saint Louis University Mental Status Examination (SLUMS)

- High school education <27
- Less than high school education <25

Brief Alzheimer's Screen (BAS) <24

Blessed Dementia Scale (BDS) >3

Clinical Dementia Rating

- Sum of boxes score > or equal to 4.5 or
- Global score greater than or equal to 1 Mo

Montreal Cognitive Assessment (MoCA) < 26

Mini-Mental Status Exam (MMSE) < 26

SUMMARY OF EVIDENCE

ACR Appropriateness Criteria® Cerebrovascular Diseases-Aneurysm, Vascular Malformation, and Subarachnoid Hemorrhage [13]

Study Design: The study design involves a detailed literature review and expert panel recommendations to establish imaging guidelines for various cerebrovascular conditions. The criteria are based on the latest evidence and expert consensus to ensure appropriate imaging procedures are selected for different clinical scenarios.

Target Population: The target population includes patients with cerebrovascular diseases such as aneurysms, vascular malformations, and SAH. Specific variants address different clinical presentations, including known acute SAH, suspected cerebral vasospasm, untreated cerebral aneurysms, previously treated cerebral aneurysms, high-risk cerebral aneurysm screening, known high-flow vascular malformations, and suspected CNS vasculitis.

Key Factors:

Imaging Recommendations: The document outlines the appropriateness of various imaging modalities, including arteriography, CTA, MRA, MRI, and ultrasound, for different clinical scenarios. Each variant provides specific recommendations based on the clinical presentation and the relative radiation level associated with each imaging procedure.

Clinical Presentations: The criteria cover a wide range of clinical presentations, from acute SAH to surveillance monitoring of untreated and treated aneurysms, as well as screening for high-risk populations and evaluation of suspected CNS vasculitis.

Expert Panel: The recommendations are developed by an expert panel on neurological imaging, including specialists from various institutions and organizations. The panel's collaboration ensures a comprehensive and well-rounded approach to imaging guidelines.

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition [2]

Study Design: The ICHD-3 is a systematic classification of headache disorders based on extensive research and clinical studies. The classification is hierarchical, allowing for detailed diagnosis from the first-digit level to the fifth. The criteria for each headache type are based on clinical features, diagnostic criteria, and evidence from field-testing studies.

Target Population: The target population includes individuals experiencing various types of headaches, ranging from primary headaches like migraines and tension-type headaches to secondary headaches attributed to other disorders. The classification is intended for use by healthcare professionals, including neurologists, general practitioners, and researchers, to diagnose and manage headache disorders.

Key Factors:

Primary Headaches: The document classifies primary headaches into categories such as migraines, tension-type headaches, and trigeminal autonomic cephalalgias. Each category includes specific diagnostic criteria, clinical features, and comments on pathophysiology and treatment.

Secondary Headaches: These are headaches attributed to other disorders, such as trauma, vascular disorders, infections, and psychiatric disorders. The classification provides criteria for diagnosing secondary headaches based on the temporal relationship between the headache and the underlying disorder.

Diagnostic Criteria: The criteria for each headache type include the number of attacks, duration, pain characteristics, associated symptoms, and exclusion of other diagnoses. For example, migraine without aura requires at least five attacks lasting 4-72 hours with specific pain characteristics and associated symptoms like nausea and photophobia.

Field Testing: The classification includes results from field-testing studies that validate the diagnostic criteria. These studies involve large populations and use advanced diagnostic methods like neuroimaging and genetic testing.

Clinical and Research Applications: The ICHD-3 is designed for both clinical practice and research. It helps clinicians diagnose and manage headache disorders and provides a standardized framework for researchers to study headache epidemiology, pathophysiology, and treatment.

ACR Appropriateness Criteria® Cerebrovascular Diseases-Stroke and Stroke-Related Conditions [11]

Study Design: The document is a guideline developed by the American College of Radiology (ACR) Appropriateness Criteria Expert Panel on Neurological Imaging. It is based on a systematic analysis of medical literature from peer-reviewed journals and follows established methodology principles such as the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) and the RAND/UCLA Appropriateness Method.

Target Population: The guidelines are intended for use by radiologists, radiation oncologists, and referring physicians in making decisions regarding radiologic imaging and treatment for patients with cerebrovascular diseases, including stroke and stroke-related conditions.

Key Factors:

Conditions Covered: The guidelines encompass a wide range of cerebrovascular diseases, including carotid stenosis, carotid dissection, intracranial large vessel occlusion, and cerebral venous sinus thrombosis. They also address complications such as intraparenchymal hemorrhage and completed ischemic strokes.

Imaging Recommendations: The document provides evidence-based guidelines for appropriate imaging examinations for diagnosis and treatment of specified medical conditions. It includes recommendations for various imaging modalities such as CT, MRI, MRA, and ultrasound.

Clinical Scenarios: The guidelines cover different clinical scenarios, including transient ischemic attack (TIA), acute ischemic stroke, recent ischemic infarct, and known intraparenchymal hemorrhage, among others.

Methodology: The guideline development and revision process involves a multidisciplinary expert panel and supports the systematic analysis of medical literature. In instances where peer-reviewed literature is lacking or equivocal, expert opinions are used to formulate recommendations.

ANALYSIS OF EVIDENCE

Shared Conclusions [2,11,13]**:**

1. **Diagnostic Imaging**: All three articles emphasize the importance of diagnostic imaging in identifying and managing cerebrovascular conditions. They discuss various imaging modalities such as CT, MRI, MRA, and CTA, highlighting their roles in diagnosing conditions like stroke, aneurysms, and vascular malformations.
2. **Clinical Guidelines**: The articles provide clinical guidelines for the management of cerebrovascular diseases. They stress the need for evidence-based approaches and the use of standardized criteria to ensure accurate diagnosis and effective treatment.
3. **Risk Factors**: Each article discusses the risk factors associated with cerebrovascular diseases, including hypertension, smoking, and genetic predispositions. They highlight the importance of identifying these risk factors to prevent and manage conditions effectively.

POLICY HISTORY

Date	Summary
July 2025	• Fixed a typo in the Neurological Symptoms or Deficits section • Edited the policy history for June 2025 to better reflect the changes that were presented at committee. No clinical changes
June 2025	• Guideline name changed from Brain CT to Brain Computed Tomography (CT) • Guideline number changed from 002 to 2008 • Added new bullet-point to the General Statement section • Updated Imaging in Known Genetic Conditions section • Checked the Medicare Advantage box in the Applicable Lines of Business table • Added a Summary of Evidence and Analysis of Evidence • Updated refences • Updated background • Updated combination section • Reorganized tumor section Clarified: • Acute and chronic HA timeframes

Date	Summary
	• Migraine aura • CVT • Cognitive impairment labs • Horner's syndrome • Follow-up shunt evaluation • Vertigo Added: • Genetic section • History of stroke • Other cranial nerve disorders to mirror Brain MRI guideline Removed: • Childhood strabismus
June 2024	• Updated references • Updated background section • Updated combination section <u>Added</u> • Updated Cancer sections • Vertigo with progressive unilateral hearing loss or **tinnitus** • Known Moyamoya disease or reversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (also to (Bran CT /CTA combo) • Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH (Brain CT/CTA combo) <u>Deleted</u> • Tumor monitoring in neurocutaneous syndromes • Pulsatile tinnitus combo section

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

Evolent Clinical Guidelines are comprehensive and inclusive of various procedural applications for each service type. Our guidelines may be used to supplement Medicare criteria when such criteria is not fully established. When Medicare criteria is determined to not be fully established, we only reference the relevant portion of the corresponding Evolent Clinical Guideline that is applicable to the specific service or item requested in order to determine medical necessity.

REFERENCES

1. Utukuri PS, Shih RY, Ajam AA, et al. ACR Appropriateness Criteria® Headache: 2022 Update. *Journal of the American College of Radiology*. 2023;20(5):S70-S93. doi:10.1016/j.jacr.2023.02.018
2. International Headache Society. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(1):1-211. doi:10.1177/0333102417738202
3. González-Quintanilla V, Madera J, Pascual J. Update on headaches associated with physical exertion. *Cephalalgia*. 2023;43(3):3331024221146989. doi:10.1177/03331024221146989
4. Hayes LL, Palasis S, Bartel TB, et al. ACR Appropriateness Criteria® Headache–Child. *Journal of the American College of Radiology*. 2018;15(5):S78-S90. doi:10.1016/j.jacr.2018.03.017
5. Trofimova A, Vey BL, Mullins ME, Wolf DS, Kadom N. Imaging of Children With Nontraumatic Headaches. *American Journal of Roentgenology*. 2018;210(1):8-17. doi:10.2214/AJR.17.18561
6. Wang LL, Thompson TA, Shih RY, et al. ACR Appropriateness Criteria® Dizziness and Ataxia: 2023 Update. *Journal of the American College of Radiology*. 2024;21(6):S100-S125. doi:10.1016/j.jacr.2024.02.018
7. Harvey HB, Watson LC, Subramaniam RM, et al. ACR Appropriateness Criteria® Movement Disorders and Neurodegenerative Diseases. *Journal of the American College of Radiology*. 2020;17(5):S175-S187. doi:10.1016/j.jacr.2020.01.042
8. Kennedy TA, Corey AS, Policeni B, et al. ACR Appropriateness Criteria® Orbits Vision and Visual Loss. *Journal of the American College of Radiology*. 2018;15(5):S116-S131. doi:10.1016/j.jacr.2018.03.023
9. Sharma A, Kirsch CFE, Aulino JM, et al. ACR Appropriateness Criteria® Hearing Loss and/or Vertigo. *Journal of the American College of Radiology*. 2018;15(11):S321-S331. doi:10.1016/j.jacr.2018.09.020
10. Soares BP, Shih RY, Utukuri PS, et al. ACR Appropriateness Criteria® Altered Mental Status, Coma, Delirium, and Psychosis: 2024 Update. *Journal of the American College of Radiology*. 2024;21(11):S372-S383. doi:10.1016/j.jacr.2024.08.018
11. Pannell JS, Corey AS, Shih RY, et al. ACR Appropriateness Criteria® Cerebrovascular Diseases-Stroke and Stroke-Related Conditions. *Journal of the American College of Radiology*. 2024;21(6):S21-S64. doi:10.1016/j.jacr.2024.02.015
12. Robertson RL, Palasis S, Rivkin MJ, et al. ACR Appropriateness Criteria® Cerebrovascular Disease-Child. *Journal of the American College of Radiology*. 2020;17(5):S36-S54. doi:10.1016/j.jacr.2020.01.036
13. Ledbetter LN, Burns J, Shih RY, et al. ACR Appropriateness Criteria® Cerebrovascular Diseases-Aneurysm, Vascular Malformation, and Subarachnoid Hemorrhage. *Journal of the American College of Radiology*. 2021;18(11):S283-S304. doi:10.1016/j.jacr.2021.08.012

14. Polinder S, Cnossen MC, Real RGL, et al. A Multidimensional Approach to Post-concussion Symptoms in Mild Traumatic Brain Injury. *Front Neurol*. 2018;9:1113. doi:10.3389/fneur.2018.01113

15. Alrajhi KN, Perry JJ, Forster AJ. Intracranial Bleeds after Minor and Minimal Head Injury in Patients on Warfarin. *J Emerg Med*. 2015;48(2):137-142. doi:10.1016/j.jemermed.2014.08.016

16. Referenced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers Version 5.2024. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.

17. American College of Radiology. *ACR Appropriateness Criteria® Brain Tumors*.; 2024.

18. Gomez CK, Schiffman SR, Bhatt AA. Radiological review of skull lesions. *Insights Imaging*. 2018;9(5):857-882. doi:10.1007/s13244-018-0643-0

19. Trofimova A, Milla SS, Ryan ME, et al. ACR Appropriateness Criteria® Seizures-Child. *Journal of the American College of Radiology*. 2021;18(5):S199-S211. doi:10.1016/j.jacr.2021.02.020

20. Lee RK, Burns J, Ajam AA, et al. ACR Appropriateness Criteria® Seizures and Epilepsy. *Journal of the American College of Radiology*. 2020;17(5):S293-S304. doi:10.1016/j.jacr.2020.01.037

21. Duong MT, Rudie JD, Mohan S. Neuroimaging Patterns of Intracranial Infections. *Neuroimaging Clin N Am*. 2023;33(1):11-41. doi:10.1016/j.nic.2022.07.001

22. Godasi R, Pang G, Chauhan S, Bollu PC. Primary Central Nervous System Vasculitis. *StatPearls*. Published online June 19, 2023. https://www.ncbi.nlm.nih.gov/books/NBK482476/

23. Health Quality Ontario. The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis. *Ont Health Technol Assess Ser*. 2014;14(1):1-64.

24. Narayanan L, Murray AD. What can imaging tell us about cognitive impairment and dementia? *World J Radiol*. 2016;8(3):240-254. doi:10.4329/wjr.v8.i3.240

25. Sharifi S, Nederveen AJ, Booij J, van Rootselaar AF. Neuroimaging essentials in essential tremor: A systematic review. *Neuroimage Clin*. 2014;5:217-231. doi:10.1016/j.nicl.2014.05.003

26. Comella CL. *Cervical Dystonia*.; 2019. https://rarediseases.org/rare-diseases/cervical-dystonia/

27. Sadaka A, Schockman SL, Golnik KC. Evaluation of Horner Syndrome in the MRI Era. *Journal of Neuro-Ophthalmology*. 2017;37(3):268-272. doi:10.1097/WNO.0000000000000503

28. Maamouri R, Ferchichi M, Houmane Y, Gharbi Z, Cheour M. Neuro-Ophthalmological Manifestations of Horner's Syndrome: Current Perspectives. *Eye Brain*. 2023;Volume 15:91-100. doi:10.2147/EB.S389630

29. Rath TJ, Policeni B, Juliano AF, et al. ACR Appropriateness Criteria® Cranial Neuropathy: 2022 Update. *Journal of the American College of Radiology*. 2022;19(11):S266-S303. doi:10.1016/j.jacr.2022.09.021

30. Choi I, Jeon SR. Neuralgias of the Head: Occipital Neuralgia. *J Korean Med Sci*. 2016;31(4):479-488. doi:10.3346/jkms.2016.31.4.479

31. Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell's palsy. *Otolaryngol Head Neck Surg*. 2013;149(3 Suppl):S1-27. doi:10.1177/0194599813505967

32. Yao L, Wang B, Lu F, He X, Lu G, Zhang S. Facial nerve in skullbase tumors: imaging and clinical relevance. *Eur J Med Res*. 2023;28(1):121. doi:10.1186/s40001-023-01078-7

33. Al-Noury K, Lotfy A. Normal and pathological findings for the facial nerve on magnetic resonance imaging. *Clin Radiol*. 2011;66(8):701-707. doi:10.1016/j.crad.2011.02.012

34. Reiss J, King RR. The epidemiology and pathophysiology of pseudobulbar affect and its association with neurodegeneration. *Degener Neurol Neuromuscul Dis*. 2013;27(3):23-31. doi:10.2147/DNND.S34160

35. Rossi A, Argyropoulou M, Zlatareva D, et al. European recommendations on practices in pediatric neuroradiology: consensus document from the European Society of Neuroradiology (ESNR), European Society of Paediatric Radiology (ESPR) and European Union of Medical Specialists Division of Neuroradiology (UEMS). *Pediatr Radiol*. 2023;53(1):159-168. doi:10.1007/s00247-022-05479-4

36. Tan AP, Mankad K, Gonçalves FG, Talenti G, Alexia E. Macrocephaly. *Topics in Magnetic Resonance Imaging*. 2018;27(4):197-217. doi:10.1097/RMR.0000000000000170

37. Hanzlik E, Gigante J. Microcephaly. *Children*. 2017;4(6):47. doi:10.3390/children4060047

38. National Guideline Alliance (UK). Cerebral palsy in under 25s: assessment and management. *National Institute for Health and Care Excellence (NICE)*. Published online 2017. https://www.ncbi.nlm.nih.gov/books/NBK419326/

39. Damasceno BP. Neuroimaging in normal pressure hydrocephalus. *Dement Neuropsychol*. 2015;9(4):350-355. doi:10.1590/1980-57642015DN94000350

40. Khalatbari H, Parisi MT. Management of Hydrocephalus in Children: Anatomic Imaging Appearances of CSF Shunts and Their Complications. *American Journal of Roentgenology*. 2021;216(1):187-199. doi:10.2214/AJR.20.22888

41. Severson M, Schaurich CG, Strecker-McGraw MK. Cerebrospinal Fluid Leak. *StatPearls*. Published online March 6, 2023. https://www.ncbi.nlm.nih.gov/books/NBK538157/

42. Hiremath SB, Gautam AA, Sasindran V, Therakathu J, Benjamin G. Cerebrospinal fluid rhinorrhea and otorrhea: A multimodality imaging approach. *Diagn Interv Imaging*. 2019;100(1):3-15. doi:10.1016/j.diii.2018.05.003

43. Hatgaonkar AM, Mahajan SM, Hatgoankar KA, Bandre GR. MRI Imaging Insights in Chiari Malformation Type 1 and Variations With Hydrosyringomyelia. *Cureus*. 2024;16(3):e55676. doi:10.7759/cureus.55676

44. Mohammad SA, Osman NM, Ahmed KA. The value of CSF flow studies in the management of CSF disorders in children: a pictorial review. *Insights Imaging*. 2019;10(1):3. doi:10.1186/s13244-019-0686-x

45. Hidalgo JA, Tork CA, Varacallo MA. Arnold-Chiari Malformation. *StatPearls*. Published online September 4, 2023. https://www.ncbi.nlm.nih.gov/books/NBK431076/

46. Deline C. Spontaneous Intracranial Hypotension. National Organization for Rare Disorders. May 29, 2024. https://rarediseases.org/rare-diseases/spontaneous-intracranial-hypotension/

47. Felix O, Amaddeo A, Olmo Arroyo J, et al. Central sleep apnea in children: experience at a single center. *Sleep Med*. 2016;25:24-28. doi:10.1016/j.sleep.2016.07.016

48. Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. *Eur Heart J*. 2018;39(21):1883-1948. doi:10.1093/eurheartj/ehy037

49. Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. *Neurogastroenterology & Motility*. 2019;31(S2):e13604. doi:10.1111/nmo.13604

50. Raucci U, Borrelli O, Di Nardo G, et al. Cyclic Vomiting Syndrome in Children. *Front Neurol*. 2020;11:583425. doi:10.3389/fneur.2020.583425

51. Luttrull MD, Boulter DJ, Kirsch CFE, et al. ACR Appropriateness Criteria® Acute Mental Status Change, Delirium, and New Onset Psychosis. *Journal of the American College of Radiology*. 2019;16(5):S26-S37. doi:10.1016/j.jacr.2019.02.024

52. Randhawa HS, Bagale S, Umap R, Randhawa J. Brain Magnetic Resonance Imaging-Based Evaluation of Pediatric Patients With Developmental Delay: A Cross-Sectional Study. *Cureus*. Published online April 11, 2022:e24051. doi:10.7759/cureus.24051

53. Tieder JS, Bonkowsky JL, Etzel RA, et al. Brief Resolved Unexplained Events (Formerly Apparent Life-Threatening Events) and Evaluation of Lower-Risk Infants: Executive Summary. *Pediatrics*. 2016;137(5):e20160591. doi:10.1542/peds.2016-0591

54. Legare JM. Achondroplasia. *GeneReviews®*. Published online May 11, 2023. https://www.ncbi.nlm.nih.gov/books/NBK1152/

55. Bender M, Carlberg K. Sickle Cell Disease. *GeneReviews®*. Published online February 13, 2025. https://www.ncbi.nlm.nih.gov/books/NBK1377/

56. DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. *Blood Adv*. 2020;4(8):1554-1588. doi:10.1182/bloodadvances.2019001142

57. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke*. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375

58. Gonzalez NR, Amin-Hanjani S, Bang OY, et al. Adult Moyamoya Disease and Syndrome: Current Perspectives and Future Directions: A Scientific Statement From the American

Heart Association/American Stroke Association. *Stroke*. 2023;54(10):e465-e479. doi:10.1161/STR.0000000000000443

59. Burton TM, Bushnell CD. Reversible Cerebral Vasoconstriction Syndrome. *Stroke*. 2019;50(8):2253-2258. doi:10.1161/STROKEAHA.119.024416

60. Zuccoli G, Pipitone N, Haldipur A, Brown RD, Hunder G, Salvarani C. Imaging findings in primary central nervous system vasculitis. *Clin Exp Rheumatol*. 2011;29(1 Suppl 64):S104-S109.

61. Patel DM, Weinberg BD, Hoch MJ. CT Myelography: Clinical Indications and Imaging Findings. *RadioGraphics*. 2020;40(2):470-484. doi:10.1148/rg.2020190135

62. Salvetat ML, Pellegrini F, Spadea L, Salati C, Zeppieri M. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION): A Comprehensive Overview. *Vision*. 2023;7(4):72. doi:10.3390/vision7040072